Research graph
References from Rimegepant for vestibular and cochlear symptoms associated with vertigo in a real-world retrospective study. Local targets link to admitted publications; unresolved targets remain external evidence.
Vertigo: Streamlining the Evaluation through Symptom Localization
10.1016/j.mcna.2021.05.011 · 2021 · External reference
A review of primary care referrals for patients with dizziness and vertigo: prevalence and demographics
10.1007/s11845-021-02575-6 · 2022 · External reference
The epidemiology of dizziness and vertigo
10.1016/b978-0-444-63437-5.00005-4 · 2016 · External reference
Vestibular Disorders
10.1016/j.pop.2024.09.004 · 2025 · External reference
Etiologic distribution of dizziness/vertigo in a neurological outpatient clinic according to the criteria of the international classification of vestibular disorders: a single-center study
10.1007/s00415-023-12166-3 · 2024 · External reference
Headache Disorders: Differentiating Primary and Secondary Etiologies
10.31083/j.jin2302043 · 2024 · External reference
Hearing Loss and Tinnitus
10.1016/j.mcna.2021.05.003 · 2021 · External reference
Association of Benign Paroxysmal Positional Vertigo with Depression and Anxiety-A Systematic Review and Meta-Analysis
10.1002/lary.30957 · 2024 · External reference
Anxiety and Depression in Adults With Vestibular Disorders: A Systematic Review and Meta-Analysis
10.1002/lary.70055 · 2025 · External reference
Hearing Loss, Hearing Aids, and Cognition
10.1001/jamanetworkopen.2024.36723 · 2024 · External reference
Hearing loss and cognitive impairment among older adults: findings from the China health and retirement longitudinal study
10.1186/s12889-025-22860-8 · 2025 · External reference
Association between dizziness and future falls and fall-related injuries in older adults: a systematic review and meta-analysis
10.1093/ageing/afae177 · 2024 · External reference
Diagnosis and treatment of vertigo and dizziness : Interdisciplinary guidance paper for clinical practice
10.1007/s00106-025-01599-z · 2025 · External reference
Efficacy of high dose systemic versus combined (systemic and intratympanic) corticosteroid therapy in idiopathic sudden sensorineural hearing loss: A prospective randomized trial and risk factor analysis
10.1016/j.amjoto.2023.104099 · 2024 · External reference
Salvage treatment strategies for refractory sudden sensorineural hearing loss-a comprehensive review and meta-analysis with practical recommendations
10.3389/fneur.2025.1627892 · 2025 · External reference
Intratympanic gentamicin for Ménière's disease
2023 · External reference
Serotonin-induced plasma extravasation in the murine inner ear: possible mechanism of migraine-associated inner ear dysfunction
10.1111/j.1468-2982.2006.01208.x · 2006 · External reference
Migraine and the trigeminovascular system-40 years and counting
10.1016/s1474-4422(19)30185-1 · 2019 · External reference
Exploring Heterogeneity in Vestibular Migraine Using Individualized Differential Structural Covariance Network Analysis
10.1111/cns.70599 · 2025 · External reference
Trigeminal ganglion innervation of the cochlea--a retrograde transport study
10.1016/s0306-4522(96)00641-0 · 1997 · External reference
Direct evidence of trigeminal innervation of the cochlear blood vessels
10.1016/s0306-4522(97)00503-4 · 1998 · External reference
Ménière's disease and vestibular migraine: a narrative review of pathogenetic insights, diagnostic evolution, and clinical management advances
10.3389/fneur.2025.1653509 · 2025 · External reference
[Neuropeptide effects on the trigeminal system: pathophysiology and clinical significance for migraine]
2011 · External reference
Neurokinins and their receptors in the rat trigeminal system: Differential localization and release with implications for migraine pain
10.1177/17448069211059400 · 2021 · External reference
Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: Relevant to migraine
10.1177/1744806918820452 · 2019 · External reference
Calcitonin gene-related peptide in the audiovestibular system
10.1111/head.15075 · 2025 · External reference
Systemic calcitonin gene-related peptide modifies auditory and vestibular end organ electrical potentials, and increases sensory hypersensitivities
10.1152/jn.00226.2024 · 2025 · External reference
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental chronic migraine rat model
10.1186/s10194-022-01403-1 · 2022 · External reference
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
10.1152/physrev.00059.2021 · 2023 · External reference
Treating Menière's disease with rimegepant
10.57187/s.4147 · 2025 · External reference
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update
10.1186/s10194-022-01431-x · 2022 · External reference
Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study
10.1186/s10194-025-02243-5 · 2025 · External reference
A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
10.1111/head.14835 · 2024 · External reference
Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study
10.1177/03331024231161809 · 2023 · External reference
Menière's disease caused by CGRP - A new hypothesis explaining etiology and pathophysiology. Redirecting Menière's syndrome to Menière's disease
10.3233/ves-200716 · 2021 · External reference
CGRP Modulating Therapies: An Update
10.1007/s11910-024-01363-w · 2024 · External reference
Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, in Healthy Chinese Participants
10.1002/cpdd.1599 · 2025 · External reference
Pharmacokinetics and Safety of Single and Multiple Daily Dosing of 75-mg Rimegepant Orally Disintegrating Tablets in Healthy Chinese Adults: A Randomized Placebo-Controlled Trial
10.1002/cpdd.1230 · 2023 · External reference
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review
10.2165/00003088-200140030-00004 · 2001 · External reference
Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
10.2147/dddt.s380440 · 2023 · External reference
Ibuprofen: pharmacology, efficacy and safety
10.1007/s10787-009-0016-x · 2009 · External reference
The 5-HT(1F) receptor as the target of ditans in migraine - from bench to bedside
10.1038/s41582-023-00842-x · 2023 · External reference
Effect of Galcanezumab on PHQ-9 and GAD-7 in Patients with Migraine: A Real-world Study in Japan
10.2169/internalmedicine.5856-25 · 2025 · External reference
Impact of Erenumab on Comorbid Depression, Anxiety, and Sleep Quality in Migraine: A Registry for Migraine (REFORM) Study
10.1111/ene.70402 · 2025 · External reference
Vestibular migraine: Diagnostic criteria1
10.3233/ves-201644 · 2022 · External reference
Clinical Practice Guideline: Ménière's Disease
2020 · External reference
The world report on hearing, 2021
10.2471/blt.21.285643 · 2021 · External reference
A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine
10.1177/03331024251355947 · 2025 · External reference
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention
10.1186/s10194-025-02225-7 · 2025 · External reference
Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG)
10.1186/s13063-019-3903-5 · 2019 · External reference
Hearing Loss, Hearing Aids, and Cognition
10.1001/jamanetworkopen.2024.36723 · ExternalCitation · doi-reference
Pharmacokinetics and Safety of Single and Multiple Daily Dosing of 75-mg Rimegepant Orally Disintegrating Tablets in Healthy Chinese Adults: A Randomized Placebo-Controlled Trial
10.1002/cpdd.1230 · ExternalCitation · doi-reference
Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, in Healthy Chinese Participants
10.1002/cpdd.1599 · ExternalCitation · doi-reference
Association of Benign Paroxysmal Positional Vertigo with Depression and Anxiety-A Systematic Review and Meta-Analysis
10.1002/lary.30957 · ExternalCitation · doi-reference
Anxiety and Depression in Adults With Vestibular Disorders: A Systematic Review and Meta-Analysis
10.1002/lary.70055 · ExternalCitation · doi-reference
Diagnosis and treatment of vertigo and dizziness : Interdisciplinary guidance paper for clinical practice
10.1007/s00106-025-01599-z · ExternalCitation · doi-reference
Etiologic distribution of dizziness/vertigo in a neurological outpatient clinic according to the criteria of the international classification of vestibular disorders: a single-center study
10.1007/s00415-023-12166-3 · ExternalCitation · doi-reference
Ibuprofen: pharmacology, efficacy and safety
10.1007/s10787-009-0016-x · ExternalCitation · doi-reference
A review of primary care referrals for patients with dizziness and vertigo: prevalence and demographics
10.1007/s11845-021-02575-6 · ExternalCitation · doi-reference
CGRP Modulating Therapies: An Update
10.1007/s11910-024-01363-w · ExternalCitation · doi-reference
The epidemiology of dizziness and vertigo
10.1016/b978-0-444-63437-5.00005-4 · ExternalCitation · doi-reference
Efficacy of high dose systemic versus combined (systemic and intratympanic) corticosteroid therapy in idiopathic sudden sensorineural hearing loss: A prospective randomized trial and risk factor analysis
10.1016/j.amjoto.2023.104099 · ExternalCitation · doi-reference
Hearing Loss and Tinnitus
10.1016/j.mcna.2021.05.003 · ExternalCitation · doi-reference
Vertigo: Streamlining the Evaluation through Symptom Localization
10.1016/j.mcna.2021.05.011 · ExternalCitation · doi-reference
Vestibular Disorders
10.1016/j.pop.2024.09.004 · ExternalCitation · doi-reference
Trigeminal ganglion innervation of the cochlea--a retrograde transport study
10.1016/s0306-4522(96)00641-0 · ExternalCitation · doi-reference
Direct evidence of trigeminal innervation of the cochlear blood vessels
10.1016/s0306-4522(97)00503-4 · ExternalCitation · doi-reference
Migraine and the trigeminovascular system-40 years and counting
10.1016/s1474-4422(19)30185-1 · ExternalCitation · doi-reference
The 5-HT(1F) receptor as the target of ditans in migraine - from bench to bedside
10.1038/s41582-023-00842-x · ExternalCitation · doi-reference
Association between dizziness and future falls and fall-related injuries in older adults: a systematic review and meta-analysis
10.1093/ageing/afae177 · ExternalCitation · doi-reference
Exploring Heterogeneity in Vestibular Migraine Using Individualized Differential Structural Covariance Network Analysis
10.1111/cns.70599 · ExternalCitation · doi-reference
Impact of Erenumab on Comorbid Depression, Anxiety, and Sleep Quality in Migraine: A Registry for Migraine (REFORM) Study
10.1111/ene.70402 · ExternalCitation · doi-reference
A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
10.1111/head.14835 · ExternalCitation · doi-reference
Calcitonin gene-related peptide in the audiovestibular system
10.1111/head.15075 · ExternalCitation · doi-reference
Serotonin-induced plasma extravasation in the murine inner ear: possible mechanism of migraine-associated inner ear dysfunction
10.1111/j.1468-2982.2006.01208.x · ExternalCitation · doi-reference
Systemic calcitonin gene-related peptide modifies auditory and vestibular end organ electrical potentials, and increases sensory hypersensitivities
10.1152/jn.00226.2024 · ExternalCitation · doi-reference
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
10.1152/physrev.00059.2021 · ExternalCitation · doi-reference
Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study
10.1177/03331024231161809 · ExternalCitation · doi-reference
A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine
10.1177/03331024251355947 · ExternalCitation · doi-reference
Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: Relevant to migraine
10.1177/1744806918820452 · ExternalCitation · doi-reference
Neurokinins and their receptors in the rat trigeminal system: Differential localization and release with implications for migraine pain
10.1177/17448069211059400 · ExternalCitation · doi-reference
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental chronic migraine rat model
10.1186/s10194-022-01403-1 · ExternalCitation · doi-reference
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update
10.1186/s10194-022-01431-x · ExternalCitation · doi-reference
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention
10.1186/s10194-025-02225-7 · ExternalCitation · doi-reference
Effectiveness of rimegepant in vestibular migraine: a prospective self-controlled cohort study
10.1186/s10194-025-02243-5 · ExternalCitation · doi-reference
Hearing loss and cognitive impairment among older adults: findings from the China health and retirement longitudinal study
10.1186/s12889-025-22860-8 · ExternalCitation · doi-reference
Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG)
10.1186/s13063-019-3903-5 · ExternalCitation · doi-reference
Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
10.2147/dddt.s380440 · ExternalCitation · doi-reference
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review
10.2165/00003088-200140030-00004 · ExternalCitation · doi-reference
Effect of Galcanezumab on PHQ-9 and GAD-7 in Patients with Migraine: A Real-world Study in Japan
10.2169/internalmedicine.5856-25 · ExternalCitation · doi-reference
The world report on hearing, 2021
10.2471/blt.21.285643 · ExternalCitation · doi-reference
Headache Disorders: Differentiating Primary and Secondary Etiologies
10.31083/j.jin2302043 · ExternalCitation · doi-reference
Menière's disease caused by CGRP - A new hypothesis explaining etiology and pathophysiology. Redirecting Menière's syndrome to Menière's disease
10.3233/ves-200716 · ExternalCitation · doi-reference
Vestibular migraine: Diagnostic criteria1
10.3233/ves-201644 · ExternalCitation · doi-reference
Salvage treatment strategies for refractory sudden sensorineural hearing loss-a comprehensive review and meta-analysis with practical recommendations
10.3389/fneur.2025.1627892 · ExternalCitation · doi-reference
Ménière's disease and vestibular migraine: a narrative review of pathogenetic insights, diagnostic evolution, and clinical management advances
10.3389/fneur.2025.1653509 · ExternalCitation · doi-reference
Treating Menière's disease with rimegepant
10.57187/s.4147 · ExternalCitation · doi-reference
